A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
Inclusion Criteria:
Exclusion Criteria: